Jyong Biotech (MENS) Competitors $59.80 +4.99 (+9.10%) As of 09/2/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock MENS vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, VRNA, ELAN, ROIV, and GRFSShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Grifols Jyong Biotech (NASDAQ:MENS) and Viatris (NASDAQ:VTRS) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations. Do analysts prefer MENS or VTRS? Viatris has a consensus target price of $10.40, suggesting a potential downside of 1.33%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has preferable valuation & earnings, MENS or VTRS? Jyong Biotech has higher earnings, but lower revenue than Viatris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AViatris$14.74B0.83-$634.20M-$2.90-3.63 Does the media refer more to MENS or VTRS? In the previous week, Viatris had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Viatris and 0 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.47 beat Viatris' score of 0.05 indicating that Jyong Biotech is being referred to more favorably in the media. Company Overall Sentiment Jyong Biotech Positive Viatris Neutral Do insiders and institutionals have more ownership in MENS or VTRS? 79.9% of Viatris shares are held by institutional investors. 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is MENS or VTRS more profitable? Jyong Biotech has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Jyong Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Viatris -24.57%16.54%7.06% SummaryViatris beats Jyong Biotech on 9 of the 11 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$4.55B$878.12M$2.51B$9.76BDividend YieldN/A4.84%2.54%4.49%P/E RatioN/A1.1226.3126.39Price / SalesN/A26.8998.62108.99Price / CashN/A19.5623.5128.92Price / BookN/A6.5527.756.58Net IncomeN/A-$5.07M$16.40M$265.84M7 Day Performance16.80%0.24%0.83%-0.26%1 Month Performance212.76%9.25%4.94%5.82%1 Year PerformanceN/A23.89%29.19%22.47% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$59.80+9.1%N/AN/A$4.55BN/A0.0031News CoveragePositive NewsGap UpVTRSViatris1.7948 of 5 stars$10.55-0.9%$10.40-1.4%-12.6%$12.42B$14.74B4.4232,000RDYDr. Reddy's Laboratories2.7386 of 5 stars$14.46-0.4%$16.95+17.3%-15.5%$12.11B$3.81B21.9927,811Positive NewsASNDAscendis Pharma A/S3.4507 of 5 stars$190.37-2.0%$243.36+27.8%+43.8%$11.89B$393.54M0.001,017News CoveragePositive NewsAnalyst ForecastQGENQIAGEN4.1877 of 5 stars$48.92-1.6%$49.69+1.6%+5.6%$11.06B$1.98B21.205,765Positive NewsMRNAModerna4.4125 of 5 stars$25.35-6.5%$42.88+69.2%-68.7%$10.55B$3.24B0.005,800BBIOBridgeBio Pharma4.1704 of 5 stars$47.29-3.6%$61.35+29.7%+79.5%$9.38B$221.90M0.00400Positive NewsVRNAVerona Pharma PLC American Depositary Share2.3831 of 5 stars$105.62+0.1%$109.00+3.2%+286.1%$9.13B$42.28M0.0030News CoveragePositive NewsELANElanco Animal Health3.11 of 5 stars$17.80-0.6%$17.33-2.6%+15.5%$8.90B$4.44B19.909,000Positive NewsAnalyst RevisionROIVRoivant Sciences3.0514 of 5 stars$11.64-2.3%$16.50+41.8%+1.3%$8.14B$29.05M0.00860News CoveragePositive NewsAnalyst ForecastGRFSGrifols3.9358 of 5 stars$9.82-3.3%$10.30+4.9%+3.6%$6.99B$7.81B0.0023,822News CoveragePositive NewsGap Down Related Companies and Tools Related Companies VTRS Alternatives RDY Alternatives ASND Alternatives QGEN Alternatives MRNA Alternatives BBIO Alternatives VRNA Alternatives ELAN Alternatives ROIV Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MENS Stock Alerts